display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone OAK ...
avelumab based treatment
avelumab alone JAVELIN Lung 200 ...
durvalumab based treatment
durvalumab alone ARCTIC ...
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg) KEYNOTE-010 ... KEYNOTE-010 ...
pembrolizumab (2mg/kg) KEYNOTE-010 ... KEYNOTE-010 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons